Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Blueprint Medicines (BPMC) Reports Q4 Net Loss of $5.40
February 16, 2022 7:05 AM ESTBlueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($5.40), $3.75 worse than the analyst estimate of ($1.65). Revenue for the quarter came in at $107.02 million versus the consensus estimate of $102.69 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More